Lakewood-Amedex Expands IP Portfolio with New Australian Patent for Bisphosphocin® Compounds
Event summary
- Lakewood-Amedex Biotherapeutics secured a new patent in Australia for its Bisphosphocin® compounds, issued March 5, 2026.
- The patent covers antimicrobial compounds being developed for complicated urinary tract infections and pulmonary infections.
- The company's global IP portfolio now includes 72 granted patents and 29 pending patents across multiple countries.
- CEO Kelvin Cooper highlighted the patent as a strategic asset in addressing the global antimicrobial resistance crisis.
The big picture
Lakewood-Amedex's new patent strengthens its intellectual property foundation amid a global crisis of antimicrobial resistance, which causes over six million deaths annually. The expansion of its IP portfolio positions the company to potentially generate significant value for shareholders while addressing critical unmet medical needs. This strategic move aligns with broader industry trends toward developing novel antimicrobial solutions to combat resistant bacterial strains.
What we're watching
- IP Expansion Strategy
- How Lakewood-Amedex will leverage this patent to strengthen its global market position and attract potential partners or investors.
- Clinical Development Pace
- Whether the company can accelerate the development of Bisphosphocin® compounds for high-need antimicrobial infections, given the enhanced IP protection.
- Regulatory Approvals
- The pace at which Lakewood-Amedex can secure regulatory approvals for its Bisphosphocin® compounds in key markets, particularly those with high antimicrobial resistance burdens.
Related topics